Table 2.

Pharmacodynamic outcomes for primary endpoint PPG–AUC_{0–1  h} and secondary endpoint PPG–C_max

Parameter	Lixisenatide treatment group	Effect estimate vs placebo	90% confidence intervals	p‐value
PPG–AUC0–1 h (mmol min L−1)	2.5 µg	−61.2	−75.2, −47.3	<0.001
	5 µg	−92.3	−106.2, −78.4	<0.001
	10 µg	−118.4	−132.4, −104.4	<0.001
	20 µg	−121.1	−135.2, −107.1	<0.001
PPG–Cmax (mmol L−1)	2.5 µg	−0.8	−1.1, −0.5	<0.001
	5 µg	−1.0	−1.3, −0.7	<0.001
	10 µg	−1.5	−1.8, −1.2	<0.001
	20 µg	−1.2	−1.6, −0.9	<0.001
Parameter	Lixisenatide treatment group	Effect estimate between doses	90% confidence intervals	p‐value
PPG–AUC0–1 h (mmol min L−1)	5 µg vs 2.5 µg	−31.1	−44.7, −17.4	<0.001
	10 µg vs 2.5 µg	−57.2	−70.9, −43.4	<0.001
	20 µg vs 2.5 µg	−59.9	−73.8, −46.0	<0.001
	10 µg vs 5 µg	−26.1	−39.8, −12.4	0.002
	20 µg vs 5 µg	−28.9	−42.8, −14.9	<0.001
	20 µg vs 10 µg	−2.8	−16.7, 11.2	NS
PPG–Cmax (mmol L−1)	5 µg vs 2.5 µg	−0.3	−0.6, 0.1	NS
	10 µg vs 2.5 µg	−0.7	−1.0, −0.4	<0.001
	20 µg vs 2.5 µg	−0.5	−0.8, −0.2	0.015
	10 µg vs 5 µg	−0.5	−0.8, −0.2	0.015
	20 µg vs 5 µg	−0.2	−0.6, 0.1	NS
	20 µg vs 10 µg	0.2	−0.1, 0.6	NS

AUC, area under the curve; C_max, maximum concentration; NS, non‐significant p‐value; PPG, postprandial plasma glucose.

Data are point estimates of treatment group differences with 90% confidence intervals for lixisenatide treatment groups (2.5, 5, 10 and 20 µg) versus placebo or between lixisenatide doses.